Search results
Results from the WOW.Com Content Network
A comparison of the structures of the natural estrogen hormone estradiol (left) and one of the nonyl-phenols (right), a xenoestrogen endocrine disruptor. Endocrine disruptors, sometimes also referred to as hormonally active agents, [1] endocrine disrupting chemicals, [2] or endocrine disrupting compounds [3] are chemicals that can interfere with endocrine (or hormonal) systems. [4]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Endocrine disruptors are exogenous substances that act like hormones in the endocrine system and disrupt the physiologic function of endogenous hormones. They are sometimes also referred to as hormonally active agents , endocrine disrupting chemicals , or endocrine disrupting compounds .
Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.
Generally, drugs outlined within the ATC code A10 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Anti-diabetic drugs .
This is a list of drugs and substances that are known or suspected to cause Stevens–Johnson syndrome This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources .
It is a rare endocrine disease caused by low levels of parathyroid hormone that impact multiple organs and affects an estimated 70,000 to 90,000 people in the United States, according to the company.
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.